Market Signal Briefing

Elastic (ESTC - Free Report) came out with quarterly earnings of $0.64 per share, beating the Zacks Consensus Estimate of $0.58 per share. This compares to earnings of $0.59 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +10.34%. A quarter ago, it was expected that this software developer would post earnings of $0.42 per share when it actually produced earnings of $0.6, delivering a surprise of +42.86%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Elastic, which belongs to the Zacks Internet - Software industry, posted revenues of $423.48 million for the quarter ended October 2025, surpassing the Zacks Consensus Estimate by 1.28%. This compares to year-ago revenues of $365.36 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Elastic shares have lost about 10.9% since the beginning of the year versus the S&P 500's gain of 12.9%.

What's Next for Elastic?While Elastic has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Elastic was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.59 on $429.34 million in revenues for the coming quarter and $2.34 on $1.7 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Internet - Software is currently in the top 26% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Guidewire Software (GWRE - Free Report) , has yet to report results for the quarter ended October 2025.

This provider of software to the insurance industry is expected to post quarterly earnings of $0.66 per share in its upcoming report, which represents a year-over-year change of +53.5%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Guidewire Software's revenues are expected to be $317.24 million, up 20.7% from the year-ago quarter.

NEW YORK--(BUSINESS WIRE)---- $BFK--BlackRock Advisors, LLC announced today that, at shareholder meetings held on October 15, 2025 and November 20, 2025, shareholders of each of the closed-end funds named below (each, a “Fund” and collectively, the “Funds”) have approved the following reorganizations or mergers, as applicable (each, a “Reorganization” and collectively, the “Reorganizations”): Reorganization of BlackRock Long-Term Municipal Advantage Trust (BTA) with and into BlackRock MuniAssets Fund, I.

Billionaire investor Peter Thiel's hedge fund, Thiel Macro LLC, reported two significant sales in its 13F filing for the quarter ending September 30, 2025.

Calgary, Alberta--(Newsfile Corp. - November 20, 2025) - Tuktu Resources Ltd. (TSXV: TUK) ("Tuktu" or the "Company") is pleased to announce its financial and operating results for the three and nine months ended September 30, 2025, as well as an operations update.

Veeva Systems (VEEV - Free Report) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $1.95 per share. This compares to earnings of $1.75 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +4.62%. A quarter ago, it was expected that this provider of cloud-based software services for the life sciences industry would post earnings of $1.9 per share when it actually produced earnings of $1.99, delivering a surprise of +4.74%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Veeva, which belongs to the Zacks Medical Info Systems industry, posted revenues of $811.24 million for the quarter ended October 2025, surpassing the Zacks Consensus Estimate by 2.44%. This compares to year-ago revenues of $699.21 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Veeva shares have added about 29.8% since the beginning of the year versus the S&P 500's gain of 12.9%.

What's Next for Veeva?While Veeva has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Veeva was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.87 on $798.22 million in revenues for the coming quarter and $7.78 on $3.14 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Info Systems is currently in the top 29% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Phreesia (PHR - Free Report) , another stock in the same industry, has yet to report results for the quarter ended October 2025. The results are expected to be released on December 8.

This developer of health care software is expected to post quarterly earnings of $0.00 per share in its upcoming report, which represents a year-over-year change of +100%. The consensus EPS estimate for the quarter has been revised 50% higher over the last 30 days to the current level.

Phreesia's revenues are expected to be $120.13 million, up 12.5% from the year-ago quarter.

Copart, Inc. (CPRT - Free Report) came out with quarterly earnings of $0.41 per share, beating the Zacks Consensus Estimate of $0.4 per share. This compares to earnings of $0.37 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +2.50%. A quarter ago, it was expected that this company would post earnings of $0.37 per share when it actually produced earnings of $0.41, delivering a surprise of +10.81%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Copart, which belongs to the Zacks Auction and Valuation Services industry, posted revenues of $1.16 billion for the quarter ended October 2025, missing the Zacks Consensus Estimate by 2.55%. This compares to year-ago revenues of $1.15 billion. The company has topped consensus revenue estimates just once over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Copart shares have lost about 27.9% since the beginning of the year versus the S&P 500's gain of 12.9%.

What's Next for Copart?While Copart has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Copart was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.42 on $1.21 billion in revenues for the coming quarter and $1.68 on $4.87 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Auction and Valuation Services is currently in the bottom 16% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

FactSet Research (FDS - Free Report) , another stock in the broader Zacks Business Services sector, has yet to report results for the quarter ended November 2025.

This financial data firm is expected to post quarterly earnings of $4.39 per share in its upcoming report, which represents a year-over-year change of +0.5%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

FactSet Research's revenues are expected to be $599.48 million, up 5.4% from the year-ago quarter.

BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Announces Sale of Paradise Village Gateway.

November 20, 2025 18:32 ET

 | Source:

Mesoblast Limited

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that given the high rate of non-responsiveness to therapies in adults with severe acute graft versus host disease (aGvHD) who fail corticosteroids, and the high mortality in these patients, Mesoblast and the United States National Institutes of Health (NIH)-funded Blood and Marrow Transplant Clinical Trials Network (BMT CTN) will collaborate on a pivotal trial of Ryoncil® (remestemcel-L-rknd) as part of first-line regimen in adults with severe aGvHD refractory to corticosteroids (SR-aGvHD). The BMT CTN is a body representing U.S. centers responsible for performing approximately 80% of all U.S. allogeneic BMTs.

Dr John Levine, Chair of the BMT CTN Steering Committee and Professor of Internal Medicine and Pediatrics, Icahn School of Medicine at Mount Sinai, New York said: “We are delighted to be partnering with Mesoblast in this pivotal Phase 3 trial of Ryoncil®. We are aiming to extend the use of this potentially life-saving treatment, already approved by FDA in children and adolescents, to adults with severe SR-aGvHD.”

In Grade III/IV SR-aGvHD 44-58% of adults treated with ruxolitinib did not achieve response at Day 28 in two studies that supported FDA approval. In patients who fail ruxolitinib survival remains as low as 20-30% by 100 days.1-3 Notably, use of Ryoncil® in Mesoblast’s Expanded Access program in patients aged 12 and older with SR-aGvHD who failed ruxolitinib or other second-line agents was associated with 76% survival at Day 100.4

Mesoblast recently met with FDA to discuss the most appropriate patient population and timing of treatment in a pivotal trial of Ryoncil® for adults with severe SR-aGvHD. In order to give adult patients with severe SR-aGvHD the best chance of survival, patients will be randomized in the trial as early as possible after corticosteroid refractoriness to receive ruxolitinib alone or combined with Ryoncil®. The trial protocol will be provided to FDA in order to initiate enrollment in the first quarter of 2026.

Mesoblast Chief Executive Silviu Itescu said, “We are pleased to be partnering with the BMT CTN to expand the availability of Ryoncil® to adult patients with severe SR-aGvHD given the poor outcome with existing therapies. This clearly remains a major unmet need and a market opportunity 3-4 times larger than the pediatric market.”

About Mesoblast
Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.

Mesoblast’s Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.

Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.

About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets.

About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and X: @Mesoblast

About the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)
The BMT CTN conducts rigorous multi-institutional clinical trials of high scientific merit, focused on improving survival for patients undergoing hematopoietic cell transplantation and/or receiving cellular therapies. The BMT CTN has completed accrual to 52 Phase II and III trials at more than 125 transplant centers and enrolled over 16,600 study participants. BMT CTN is funded by the National Heart, Lung and Blood Institute and the National Cancer Institute, both parts of the National Institutes of Health, and is a collaborative effort of 19 Core Transplant Centers/Consortia, The Center for International Blood and Marrow Transplant Research (CIBMTR), the National Marrow Donor Program (NMDP) and the Emmes Company, LLC, a clinical research organization. CIBMTR is a research collaboration between the NMDP and the Medical College of Wisconsin (MCW). Together, MCW, NMDP and Emmes have been providing research support to the BMT CTN since 2001, as the Network’s data and coordinating center. More information about the BMT CTN can be found at www.bmtctn.net

About NMDP®
At NMDPSM, we believe each of us holds the key to curing blood cancers and disorders. As a global nonprofit leader in cell therapy, NMDP creates essential connections between researchers and supporters to inspire action and accelerate innovation to find life-saving cures. With the help of blood stem cell donors from the world’s most diverse registry and our extensive network of transplant partners, physicians and caregivers, we’re expanding access to treatment so that every patient can receive their life-saving cell therapy. NMDP. Find cures. Save lives. Learn more at nmdp.org.

About the Medical College of Wisconsin (MCW)
With a history dating back to 1893, the MCW is dedicated to leadership and excellence in education, patient care, research, and community engagement. More than 1,500 students are enrolled in MCW's medical school and graduate school programs in Milwaukee, Green Bay, and Central Wisconsin. MCW's School of Pharmacy opened in 2017. A major national research center, MCW is the largest research institution in the Milwaukee metro area and second largest in Wisconsin. In the last 10 years, faculty received more than $1.5 billion in external support for research, teaching, training, and related purposes. This total includes highly competitive research and training awards from the National Institutes of Health (NIH). Annually, MCW faculty direct or collaborate on more than 3,100 research studies, including clinical trials. Additionally, more than 1,800 physicians provide care in virtually every specialty of medicine for more than 2.8 million patients annually. It has a long history in hematopoietic transplantation and cellular therapy, including operating an outcomes registry of transplantation and cellular therapy outcomes and facilitating related research since 1972.

About CIBMTR®
CIBMTR® (Center for International Blood and Marrow Transplant Research®) is a nonprofit research collaboration between NMDPSM, in Minneapolis, and the Medical College of Wisconsin (MCW), in Milwaukee. CIBMTR collaborates with the global scientific community to increase survival and enrich quality of life for patients. CIBMTR facilitates critical observational and interventional research through scientific and statistical expertise, a large network of centers, and a unique database of long-term clinical data for more than 680,000 people who have received hematopoietic cell transplantation and other cellular therapies. Learn more at cibmtr.org. It is funded by the National Cancer Institute, the National Heart, Lung and Blood Institute and the National Institute for Allergy and Infectious Disease, the Health Resources and Services Administration, the Office of Naval Research, industry sponsors, MCW, and NMDP.

About Emmes
Emmes Group, a specialty, technology and AI enabled contract research organization (CRO), is advancing and modernizing clinical research to improve patient outcomes. Founded as Emmes more than 47 years ago, we became a trusted clinical research partner to the U.S. government. Today, Emmes Group is a global full-service CRO operating in 72 countries worldwide collaborating with government agencies, public-private partnerships, and biopharma innovators. Now wholly owned by New Mountain Capital, we are transforming the future of clinical research and bringing life-changing treatments closer to patients. Where human intelligence meets artificial intelligence. Learn more at www.theemmesgroup.com.

References / Footnotes

Jagasia M, et al. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020 May 14; 135(20): 1739–1749Abedin S, et al. Ruxolitinib resistance or intolerance in steroid-refractory acute graft versus-host disease — a real-world outcomes analysis. British Journal of Haematology, 2021;195:429–43Zeiser R, et al. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. N Engl J Med 2020;382:1800-1810Kurtzberg J, et al. Ryoncil (Remestemcel-L) for Third-Line Treatment of SR-aGvHD in Adolescents and Adults [Poster presentation]. 2025 Transplantation & Cellular Therapy Tandem Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for Blood and Marrow Transplant Research (CIBMTR). Forward-Looking Statements
This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive.

For more information, please contact:

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Plug Power Inc. ("Plug" or the "Company") (NASDAQ: PLUG). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Plug and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On November 13, 2025, The Washington Examiner reported that Plug was suspending plans to build six facilities to produce and liquefy zero or low-carbon hydrogen, putting at risk the $1.66 billion federal loan guarantee it obtained in January. 

On this news, Plug's stock price fell $0.48 per share, or 17.58%, over the following two trading sessions, to close at $2.25 per share on November 14, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SCHMID Group N.V. ("Schmid" or the "Company") (NASDAQ: SHMD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Schmid and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On November 17, 2025, Schmid issued a press release disclosing receipt of a staff determination letter from the Nasdaq's Listing Qualifications Department, advising the company of the staff's decision "to delist the Company's ordinary shares and warrants from Nasdaq unless the Company timely appeals the staff's determination," due to the Company's failure to file its annual report for 2024. 

On this news, Schmid's stock price fell $1.73 per share, or 31.51%, over the following two trading sessions, to close at $3.76 per share on November 18, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alibaba Group Holding Limited ("Alibaba" or the "Company") (NYSE: BABA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Alibaba and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On November 14, 2025, citing a White House memo, the Financial Times reported that Alibaba is providing technological support for Chinese military operations against targets in the United States. 

Following this news, Alibaba's American Depositary Receipt ("ADR") price fell $6.04 per ADR, or 3.78%, to close at $153.80 per ADR on November 14, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of The Home Depot, Inc. ("Home Depot" or the "Company") (NYSE: HD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Home Depot and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On November 18, 2025, Home Depot issued a press release announcing its financial results for the third quarter of fiscal 2025 and updating its guidance for fiscal 2025. Among other items, Home Depot reported earnings per share and sales that missed forecasts, attributing the results "primarily . . . to the lack of storms in the third quarter, which resulted in greater than expected pressure in certain categories." Home Depot also said that "an expected increase in demand in the third quarter did not materialize," which the Company attributed to the impact of "consumer uncertainty and continued pressure in housing." Home Depot also projected that same-store sales for the full year would only be "slightly positive," whereas it had previously expected a 1% increase, and forecast adjusted earnings per share to drop by 5%, more than the 2% decline that the Company had projected in August. 

Following this news, Home Depot's stock price fell $21.55 per share, or 6.02%, to close at $336.48 per share on November 18, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

In a significant market event, Bitcoin's price has fallen below the $90,000 threshold, currently hovering close to the mid-$80,000 range. This decline has placed Bitcoin near the lower Bollinger Band, indicating increased market volatility and testing critical support points such as the S3 pivot level.

In brief
FG Nexus sold over $31 million worth of Ethereum from its treasury holdings.
Shares in the firm sold off more than 7% amid the news, pushing its monthly loss to nearly 37%.
It's using the proceeds to repurchase shares as a benefit for shareholders, and still holds $115 million in ETH.
Shares in publicly traded Ethereum treasury firm FG Nexus (FGNX) finished the day down more than 7% following word that the firm dumped a portion of its Ethereum holdings to buy back shares. 

Formerly known as Fundamental Global, the firm raised $200 million via a private placement in July to kick-start its Ethereum treasury strategy. It acquired more than 50,000 ETH by the end of September, but has since offloaded 10,922 ETH—about $31.3 million worth at today’s price—using the proceeds to accelerate share repurchases alongside a $200 million buyback program. 

“Since commencing the buyback, we have repurchased 8% of our shares outstanding at a substantial discount to our net asset value while maintaining a strong ETH and cash balance,” said FG Nexus Chairman and CEO Kyle Cerminara, in a statement.

“We plan to continue buying back shares while our stock trades below NAV, which creates [an] increasingly asymptotic effect on our per-share valuation metrics as the number of shares outstanding declines and net asset value per share increases,” he added.

FG Nexus is the latest Ethereum treasury firm to offload some of its holdings to buy back shares. In October, ETHZilla (ETHZ) told shareholders that it had sold around $40 million worth of ETH to buy back shares. 

Other digital asset firms like SharpLink Gaming have utilized share repurchase programs when the firm’s mNAV dipped below 1 in an attempt to benefit shareholders. A firm’s mNAV or market-to-net asset value compares the company’s market cap to the value of its holdings. 

As of Wednesday, FG Nexus firm holds 40,005 ETH—about $115 million worth—and around $37 million in USDC. In total, it has repurchased around 3.4 million shares of FGNX at an average cost of $3.94. 

Shares are well below that average cost now, changing hands at $2.41 at Thursday’s closing bell. FGNX has dipped nearly 37% in the last month, and is now down more than 85% in the last six months of trading. The firm's stock is down massively since jumping above the $40 mark in August.

Its current ETH treasury holdings place FG Nexus just outside the 7 largest publicly traded Ethereum treasuries.

Daily Debrief NewsletterStart every day with the top news stories right now, plus original features, a podcast, videos and more.

Whale wallets sold 250 million XRP worth $528 million in 48 hours, applying strong downward pressure and weakening short-term market confidence.New XRP addresses surged to a monthly high as Bitwise and Caanary ETFs boosted network participation ahead next week’s ETF launches.XRP trades at $2.11 with support at $2.08, requiring sustained inflows to rebound toward $2.20 and prevent a drop below $2.00.XRP has fallen 5% this week as its ongoing decline continues despite growing institutional interest. The altcoin is struggling to recover, even with two XRP ETFs already live and two more scheduled to launch next week. 

This disconnect has raised questions about why price action remains soft.

XRP Whales Are SellingWhale activity offers the clearest explanation for the weakness. Large holders have continued selling throughout the week, adding downward pressure on XRP. In the last 48 hours alone, wallets holding between 1 million and 10 million XRP have sold more than 250 million tokens, worth over $528 million.

Sponsored

Sponsored

Whales remain highly influential due to their ability to shift liquidity and sentiment. Sustained selling from these holders signals a lack of confidence in the near-term outlook. If the selling continues, it could deepen XRP’s decline, especially as the price approaches key support levels.

Want more token insights like this? Sign up for Editor Harsh Notariya’s Daily Crypto Newsletter here.

XRP Whale Holding. Source: SantimentMacro momentum, however, paints a more nuanced picture. New XRP addresses have surged over the past week, climbing to a monthly high. This rise appears linked to the launch of Caanary Capital’s ETF (XRPC) and Bitwise’s ETF (XRP), both of which are driving renewed participation in the network.

Additional inflows are expected as Grayscale’s XRP Trust ETF (GXRP) and Franklin Templeton’s XRP ETF (XRPZ) go live on Monday. These launches are likely encouraging new users to enter the market, providing a counterweight to whale selling and offering potential support for future price stability.

XRP New Addresses. Source: GlassnodeXRP Price Continues To FallXRP trades at $2.11 at the time of writing, maintaining support at $2.08. The asset is marking a monthly low and facing mixed sentiment due to conflicting signals from whales and new entrants. Price stability will depend on whether fresh capital outweighs ongoing sell-offs.

If inflows from new addresses continue, they may offset the recent whale selling. This could help XRP rebound above $2.20 and push toward $2.28. ETF-driven demand has the potential to restore short-term momentum and encourage accumulation.

XRP Price Analysis. Source: TradingViewIf XRP breaks below the $2.08 support, the downside risk increases. The price could fall to $2.02 or slip below $2.00 if selling intensifies. Such a decline would invalidate the bullish thesis and reflect a deeper shift in market sentiment.

Disclaimer

In line with the Trust Project guidelines, this price analysis article is for informational purposes only and should not be considered financial or investment advice. BeInCrypto is committed to accurate, unbiased reporting, but market conditions are subject to change without notice. Always conduct your own research and consult with a professional before making any financial decisions. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.

The conversation around XRP has grown louder in recent months as the asset continues to gain traction through ecosystem growth, Spot XRP ETFs, and market interest. Despite this momentum, XRP still sits far below Bitcoin, the industry’s dominant cryptocurrency, when comparing total valuation. 

That gap raises a simple question: how high would the XRP price need to climb in order to actually flip Bitcoin? Data from MarketCapOf provides a direct, real-time look at what XRP’s price would be if it matched Bitcoin’s market capitalization today.

The Market Cap Required To Flip Bitcoin
Although it is currently going through a correction phase, Bitcoin has the largest presence in the crypto market by an overwhelming margin, and its market capitalization currently stands at roughly $1.84 trillion. This valuation ranks Bitcoin among the largest assets on the planet, surpassing many global corporations.

XRP, now trading around $2.14 at the time of writing, holds a market cap of approximately $128.7 billion. This means Bitcoin’s valuation is more than fourteen times larger than XRP’s. For XRP to flip Bitcoin, the cryptocurrency would need to rise to the same market capitalization that Bitcoin currently holds.

Using the circulating supply of XRP, MarketCapOf calculates how much each XRP token would be worth if it matched Bitcoin’s market cap. Based on the latest data, XRP would need to trade at $30.61 for its total valuation to equal Bitcoin’s. This is the current “flippening price,” and it reflects the direct ratio between their two market caps.

Source: Chart from MarketCapOf
To reach the level of Bitcoin’s all-time high market cap of $2.485 trillion recorded on October 6, XRP would need to climb to about $41.26 per token.

Breaking Down The Numbers
The calculation highlights how far ahead Bitcoin still is. XRP sits at roughly seven percent of Bitcoin’s total valuation, meaning the asset would need to appreciate more than fourteen times from its current level to stand on equal footing. In simple terms, an investor holding 1,000 XRP would see their position shift from about $2,140 today to more than $30,000 if the token were priced at $30.61.

This comparison does not assume any change in circulating supply, tokenomics, or macro factors. It is a clean and direct valuation exercise based purely on market capitalization. However, even in its simplicity, it shows the scale of inflows required for XRP to close the gap and flip Bitcoin’s dominance in the cryptocurrency rankings.

Recent months have seen stronger activity in the Ripple ecosystem, most especially with new partnerships and acquisitions by Ripple. Added to this is the expanding conversation around Spot XRP ETFs, which many analysts believe could introduce significant liquidity if major issuers like BlackRock, Fidelity, and Grayscale fully enter the space. The newest entrant is Bitwise, which launched its Spot XRP ETF just hours ago.

XRP trading at $2.11 on the 1D chart | Source: XRPUSDT on Tradingview.com
Featured image from iStock, chart from Tradingview.com

Metaplanet, the Japanese hotelier-turned-Bitcoin treasury, is preparing another huge capital raise via the issuance of its new Class B perpetual shares to fuel a massive Bitcoin acquisition spree.

A Thursday formal notice shows that the company plans to issue 23,610,000 Class B Preferred shares, dubbed MERCURY, at 900 yen each, raising approximately 21.2 billion yen ( roughly $135 million) through a third-party allotment to overseas institutional investors, pending approval at an extraordinary general meeting on Dec. 22, 2025.

Mercury comes with a fixed annual dividend of 4.9% on the ¥1,000 ($6.34) notional strike price. It has quarterly payments and an initial dividend of 40.40 yen ($0.26) for the period ending Dec. 31, 2025. Holders will have the right to convert the preferred shares into common stock at a $6.34 conversion price.

MERCURY offers a hybrid profile of fixed income plus long-dated upside potential tied to Bitcoin-driven appreciation in Metaplanet’s equity value.

The firm plans to allocate the majority of the net proceeds to buy more Bitcoin between December 2025 and March 2026. It also intends to allocate ¥1.67 billion (around $10.6 million) to its BTC income-generation business, and ¥3.75 billion (around $23.8 million) to redeem its 19th Series corporate bonds.

Advertisement
 

Metaplanet has now become the third Bitcoin treasury firm to introduce a preferred equity structure, following Michael Saylor’s Bitcoin behemoth Strategy (formerly known as MicroStrategy) and Strive.

The capital raise is coupled with a broader restructuring of Metaplanet’s earlier financing instruments. The company plans to cancel its 20th to 22nd series stock acquisition rights and issue new 23rd and 24th series rights to Cayman Islands–based investment fund Evo Fund.

Metaplanet — which has been dubbed “Asia’s MicroStrategy” and is the world’s fourth biggest corporate Bitcoin holder — pivoted from its core hotel and technology business to start accumulating BTC in 2024 and now holds 30,823 BTC worth nearly $2.67 billion at today’s BTC price.

The Simon Gerovich-led company aims to acquire 210,000 Bitcoin, approximately 1% of the overall supply, by 2027 as part of a master plan.

TLDR

Coinbase has launched Ether-backed loans for US customers, enabling them to borrow USDC without selling their ETH.
The Morpho DeFi lending protocol powers the new service and is available in most US states, excluding New York.
Users can borrow up to $1 million in USDC, with variable rates and liquidation risks based on market conditions.
Coinbase plans to expand this offering to include loans backed by other assets, such as staked Ether (cbETH).
The platform’s on-chain lending markets have processed over $1.25 billion in loan originations backed by $1.37 billion in collateral.

Coinbase has introduced Ether-backed loans for US customers, allowing them to borrow USDC without selling their Ether (ETH) holdings. This new service is available in most US states, excluding New York, and is powered by Morpho, a decentralized finance (DeFi) lending protocol. Customers can borrow up to $1 million in USDC, with variable rates and liquidation risks tied to market conditions.

Partnership with Morpho and Expansion Plans
In collaboration with Morpho, Coinbase now offers a new way for users to leverage their ETH for borrowing USDC. The integration of Morpho allows Coinbase customers to access DeFi lending products through its platform. Coinbase has also indicated that it plans to expand the loan offering to other crypto assets, such as staked Ether (cbETH), in the future.

Coinbase emphasized that the new product adds a flexible borrowing option for those who prefer not to sell their Ether. This feature meets the growing demand for liquidity without requiring the liquidation of digital assets. The integration of Morpho, added to Coinbase in September, has already yielded up to 10.8% on USDC holdings.

https://x.com/coinbase/status/1991523378554105980?s=20

Coinbase’s New ICO Platform Restores Access to Token Sales
According to Dune Analytics, Coinbase’s on-chain lending markets have already processed over $1.25 billion in loan originations. These loans are backed by approximately $1.37 billion in deposited collateral. As of now, more than 13,500 wallets hold active borrow positions, with around $810 million in outstanding loans.

This new lending feature comes as Coinbase continues to expand its product offerings in the US. The company’s growth is supported by regulatory developments, such as the introduction of the GENIUS Act, which established more explicit rules for stablecoins. In line with this, Coinbase has also launched new partnerships, acquisitions, and services, such as crypto staking for New York residents and a collaboration with Citigroup.

In October, Coinbase acquired Echo, a platform that helps fund early-stage projects, for $375 million. The same month, the exchange introduced a platform for initial coin offerings (ICOs), offering regulated access to token sales for US retail investors.

Lastly, on November 10, Coinbase revealed its new platform for ICOs, with plans to list one token sale per month, starting with Monad’s token sale. The platform aims to provide regulated access to token sales, restoring a service last available in 2018.

Crypto asset manager Bitwise has confirmed its spot XRP exchange-traded fund (ETF) is set to go live on the New York Stock Exchange when markets open on Thursday, in a major milestone for the XRP community.

Bitwise To Trade Under Ticker $XRP
A Bitwise Asset Management XRP ETF will begin trading on the NYSE on Thursday under the fascinating ticker symbol “XRP,” offering exposure to the fourth-largest cryptocurrency by market cap. The fund has a management fee of 0.34% that is waived for the first month on the first $500 million in assets.

“XRP is a really intriguing asset for several reasons,” Bitwise CIO Matt Hougan said in a statement. “It has operated successfully for a very long period of time at extremely low cost, it processes high transaction volumes, and it has a really strong and vibrant community of supporters.”

Having facilitated over 4 billion transactions, Bitwise believes XRP is challenging the $250 trillion cross-border payments market.

In the United States, Bitwise’s XRP will be the second spot XRP investment vehicle following Canary Capital’s XRPC.

Advertisement
 

XRP Gets Caught In Market Slide Despite Highly Anticipated Spot ETF Debuts
Although crypto exchange-traded funds provide a vehicle to draw in capital flows from institutional investors, inflows boost the price of the underlying asset when demand is high, but hurt prices when net outflows are high.

The price of XRP has fallen by roughly 15.2% over the last seven days, despite the ETF launches, according to data from CoinGecko.

Canary Capital’s XRPC launched on November 13, garnering approximately $58 million in trading volume on opening day, making it the most successful ETF debut of 2025 among both crypto and traditional ETFs.

The massive flows were unexpected, with Bloomberg’s Senior ETF Analyst Balchunas initially estimating around $17 million for XRPC. But they highlighted the increasing appetite for crypto-focused vehicles following the success of spot Bitcoin and Ethereum ETFs, and the improved regulatory backdrop for cryptocurrencies.

Grayscale and Franklin Templeton spot XRP funds could list this coming Monday.

In a January report, JPMorgan analysts projected that XRP ETFs could outperform spot Ether ETFs by attracting roughly $4 billion–$8 billion in net new assets in their first six months of trading.

XRP is trading for $2.01 at the time of writing, down 3.2% in the last 24 hours.

Could the flood of ETF launches bring back the bulls?

Cardano co-founder Charles Hoskinson claims that Trump-era hype has derailed the bull market – Cardano price predictions now find their footing.

TLDR

Tether has acquired Parfin, a digital asset custody platform based in London and Rio de Janeiro.
The acquisition allows Tether to expand its presence in Latin America, a rapidly growing crypto hub.
Parfin specializes in custody, tokenization, and settlement, enhancing Tether’s blockchain capabilities.
Tether aims to increase USDT adoption among institutional clients in the Latin American market.
Parfin’s integration with financial institutions positions it as a strategic partner for Tether in the region.

Tether, the world’s largest stablecoin issuer, has acquired Parfin, a digital asset custody platform based in London and Rio de Janeiro. The acquisition, announced on November 20, highlights Tether’s strategy to grow its presence in Latin America. This move positions the company to more effectively bridge traditional finance and blockchain technology.

Tether’s Investment in Parfin and Latin America
Tether has been increasing its focus on Latin America, one of the world’s fastest-growing crypto hubs. The company believes the region’s financial landscape offers excellent opportunities for blockchain adoption. Paolo Ardoino, CEO of Tether, stated, “Parfin has shown a strong commitment to bridging this gap” between traditional finance and blockchain technology.

Parfin’s expertise in custody, tokenization, and settlement will allow Tether to enhance its offerings in the region. The company aims to expand USDT adoption among institutional clients. Ardoino emphasized that Tether values global access to financial freedom and sees Latin America as a vital part of that vision.

Parfin’s integration with Latin America’s financial institutions positions it as a strategic partner for Tether. The company provides custody, tokenization, and trading solutions, making it a key player in the region’s crypto market. Its platform serves institutional clients, including banks and asset managers, which strengthens Tether’s position in the market.

Marcos Viriato, CEO of Parfin, commented, “Our vision is to accelerate the integration of tokenization applications and USDT into institutional-grade blockchain solutions.” This partnership with Tether further solidifies Parfin’s role in helping institutions navigate the crypto space.

Stablecoins Power Cross-Border Transactions in LATAM
Latin America has become a key region for crypto adoption, with transaction volumes reaching nearly $1.5 trillion by October 2025. Stablecoins, like USDT, are increasingly used for remittances and cross-border transactions in the region. These digital assets offer a cheaper, faster way to transfer money, particularly important for users in countries with high inflation rates.

Parfin, which raised $10 million in Series A funding in 2024, is well-positioned to capitalize on the region’s growing interest in blockchain. Mastercard incubated the startup and offers solutions that align with both traditional finance and decentralized finance (DeFi) requirements. With clients such as Banco BV and Núclea, Parfin’s influence is expanding in Latin America.

Avalanche (AVAX) is trading at a delicate point in the market as price movement, technical structure, and upcoming ecosystem developments converge. The cryptocurrency posted mild gains over the past 24 hours, but investors remain cautious following a difficult week marked by broader market turbulence.

Solana ETFs have seen a 17-day streak of net inflows, accumulating nearly half a billion dollars in sharp contrast to recent outflows from established bitcoin and ether ETFs. In today's "Chart of the Day," presented by Crypto.com, CoinDesk's Jennifer Sanasie breaks down what this consistent demand highlights.

Ethereum briefly dropped to $2,872, tagging a key on-chain support zone that analyst MAC_D says resembles a “classic bottom.”

Ethereum (ETH) briefly touched a critical low of $2,870 on Wednesday, testing a vital on-chain support level that has historically signaled market bottoms.

According to an on-chain assessment by analyst MAC_D, this price point represents a cluster of the ‘realized price’ for both retail and large-scale investors, suggesting a potential foundation for a rebound is forming even as smaller wallets sell off.

$2.8K Realized Price Cluster Marks “Classic Bottom” Zone
In their latest report on CryptoQuant, MAC_D noted that, historically, such realized price zones have often marked major bottom areas, as long-term investors step in while short-term traders exit.

The market technician pointed out that the latest drop below $2,900, driven by risk-off sentiment before Nvidia’s earnings report, was followed by a swift rebound after the chipmaker beat expectations, lifting both U.S. equities and crypto.

At the same time, there is a clear split in behavior, with smaller wallets selling into weakness, while whale wallets holding over 10,000 ETH have kept accumulating as prices go lower. According to the expert, that shift in supply from impatient traders to larger, long-term players is also typically seen during late-stage bottom formation.

In addition, liquidation data also points to fading forced-selling pressure. MAC_D highlighted that each fresh local low now comes with a much smaller wave of long liquidations, suggesting over-leveraged bulls may have already been flushed out.

Meanwhile, short positioning has grown, meaning even a modest bounce could squeeze bears in what remains a relatively thin order-book environment.

You may also like:

$180M Liquidated in 1 Hour as BTC, ETH, and XRP Crash Harder

ETH Leverage Soars While Price Stalls – A Major Risk Signal?

Retail Fear Hits BTC, ETH, and XRP: But Analysts Say It’s a Bullish Catalyst

High Leverage and Key Liquidity Zones
At the market, Ethereum’s performance has been challenging. While its current value of around $3,020 per CoinGecko represents a slight 1% dip in the last 24 hours, it is down almost 15% over the past week and an even more dire 22% across the last month.

At the same time, the asset’s estimated leverage ratio (ELR) on Binance recently hit a record 0.5617 as the price drifted in a tight band around $3,000. And with both long and short traders piling in while spot remains relatively flat, experts at Arab Chain warned that the market is “building internal pressure” and is increasingly prone to a violent break in either direction.

Observers are also watching nearby liquidity pockets as potential magnets for the next move. Analyst Crypto Patel noted on November 19 that Ethereum had confirmed a “Break of Structure” at $2,940, but identified a zone of price inefficiency, known as a “Fair Value Gap,” between $3,270 and $3,360. They estimated that a move to fill this gap would require a 14 to 15% increase from current levels.

Tags:

flash news

MEXC Partners With Hacken for Monthly Proof-of-Reserves Audits

MEXC announced the expansion of its partnership with Hacken to implement monthly independently verified Proof-of-Reserves audits. The reports will confirm that users’ assets are fully

flash news

Tether Invests in Parfin to Expand Institutional Digital Asset Use in Latin America

Tether announced today an investment in Parfin to accelerate the institutional use of USDT and enhance blockchain-based settlement in Latin America. The company aims for

Companies

VerifiedX Teams Up With Crypto.com to Deliver Institutional Custody and Liquidity

TL;DR Crypto.com agreed to provide institutional custody, liquidity support, and OTC trading for $1.5 billion in assets within the VerifiedX ecosystem. The agreement offers institutions

Bitcoin News

New Bill Would Let Americans Pay Taxes in Bitcoin, Building National Reserve

TL;DR The “Bitcoin for America Act” bill was introduced by Ohio Congressman Warren Davidson. The main goal is to diversify national wealth with BTC to

flash news

Analyst: Bitcoin’s Price Now Driven by Dollar Strength, Not ETFs or Market Sentiment

Analyst Jamie Coutts stated that Bitcoin’s recent price movements are being driven primarily by the strength of the U.S. dollar, rather than cryptocurrency ETFs or

Solana News

Solana’s Mystery Teaser Sparks Market Excitement, SOL Price Moves Up and Down

TL;DR SOL price reached $132.85 after Solana posted a short message on its official X account stating, “Something big is coming.” The teaser generated immediate